Barcelona, June 6, 2015 - Mobile Chamber Experts GmbH (MCX) - a provider of mobile chambers for clinical testing of allergic patients - exhibits the first mobile chamber in Europe at the annual congress of EAACI
(European Academy of Allergy and Clinical Immunology) in Barcelona. 'The mobility of the chamber makes it possible to place it everywhere, and we have a unique opportunity to let potential sponsors of clinical trials and researchers visit the chamber here in Barcelona', Steen Thaarup, Managing Director of MCX, says.
'The mobile chamber, called the GA2LEN chamber, is a real breakthrough in the field of airways allergy research', Prof. Dr. med. Dr. h. c. Torsten Zuberbier, Charité-Universitätsmedizin Berlin, says. 'a completely novel technology and concept allows us to expose patients to allergens like pollen in a controlled setting and even different allergens in one trial run as the nine seats can all be exposed individually without interference.
Due to the high mobility in the standard chamber solution for the first time this can also be used in collaboration with our network in multicenter trials. Thus a GA²LEN doctor and nurse can travel with the chamber allowing highest reproducibility.'
Prof. Dr. Zuberbier is also secretary general of the Global Asthma and Allergy European Network (GA2LEN).
GA2LEN is a Network of Excellence of the leading European clinical and research facilities in the field of allergology and asthma. GA2LEN founded MCX with the support of three biopharmaceutical companies involved in allergy, Allergopharma, Leti and Stallergenes, who are also exhibiting at the EAACI.
According to Steen Thaarup, Managing Director of MCX, 'The GA2LEN chamber is a huge step forward for patients, public authorities and pharmaceutical companies. The mobility of the chamber makes it convenient for patients to take part in clinical testing, since the chamber will come to them - not the reverse. The regulatory bodies welcome this initiative to ensure that allergy pharmaceuticals are tested with the certainty of exposing the patients to the allergens they do not tolerate. In addition, the pharmaceutical companies will be able to generate clinical data faster with better validity'.
The advantages of using a Mobile Allergen Exposure Chamber makes it very convenient for clinical trials - not the least in a multi-center design. The chamber can become operational after 4 hours of arrival, and it takes even less time to dis-assemble it. This has positive influence on the time, thus on the costs - meaning in combination with the certainty of exposure, it is a very efficient way to generate valid data. Nine patients can be present at the time in the chamber, and the capacity is up to 180 exposures per week depending on the protocol.
The chamber is operated by a team from MCX, including technical and clinical personnel. The centers taking part in the study will normally recruit the patients and have a clinical person speaking the local language.

To continue reading this noodl, please get the original version here.

distributed by